Effect of an aminocardenolide and digoxin upon atrioventricular refractory period in the dog

R. W. Caldwell, C. B. Nash

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

The ability of digoxin and a 4-aminocardenolide, ASI-222, to alter atrioventricular nodal refractory period (AVRP) was determined as a function of the maximum subarrhythmic dose (MSAD) in the dog anesthetized with morphine-pentobarbital. ASI-222, a highly polar and potent inhibitor of Na+, K+-adenosine triphosphatase produces a cardiotoxicity in dogs prominently involving atrioventricular nodal blockade rather than ventricular premature ectopic beats and tachycardia seen with digoxin. AVRP was assessed with trains of electrically isolated stimuli of decreasing pulse interval delivered to the right atria. Digoxin and ASI-222 were infused i.v. at rates which produced cardiac arrhythmias in about 100 min in dogs either: with intact nerves, pretreated with atropine, without reflex receptors (without vagus and carotid sinus nerves, without cardiac sympathetic nerves and adrenals or pretreated with metoprolol. In dogs with intact nerves, ASI-222 produced greater increases in AVRP than digoxin at fractions of the MSAD; however, both glycoside produced a similar elevation at the MSAD (~30% increase). Atropine did not alter the AVRP response to ASI-222 but prevented the lengthening due to digoxin except for that which occurred near the MSAD. Removal of reflex receptor afferents (and vagi) had an effect similar to atropine on the AVRP response to digoxin, but completely prevented any response to ASI-222. Prior sympathectomy or beta adrenergic blockade abolished the AVRP response to ASI-222 but did not alter the responses to digoxin. Our data indicate that ASI-222 increases AVRP by inhibiting cardiac sympathetic nervous influences in contrast to the effects of digoxin which are exerted mainly through vagal and direct means. Furthermore, they suggest the aminocardenolide increases AVRP more effectively at subarrhythmic doses than does digoxin.

Original languageEnglish (US)
Pages (from-to)583-588
Number of pages6
JournalJournal of Pharmacology and Experimental Therapeutics
Volume235
Issue number3
StatePublished - Dec 1 1985

Fingerprint

Digoxin
Dogs
Atropine
Reflex
Premature Cardiac Complexes
Carotid Sinus
Metoprolol
Aptitude
Sympathectomy
Ventricular Premature Complexes
ASI-222
Pentobarbital
Glycosides
Heart Atria
Tachycardia
Adrenergic Agents
Morphine
Adenosine Triphosphatases
Cardiac Arrhythmias

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology

Cite this

Effect of an aminocardenolide and digoxin upon atrioventricular refractory period in the dog. / Caldwell, R. W.; Nash, C. B.

In: Journal of Pharmacology and Experimental Therapeutics, Vol. 235, No. 3, 01.12.1985, p. 583-588.

Research output: Contribution to journalArticle

@article{8189169a25a94d39adf366e1b5f16bef,
title = "Effect of an aminocardenolide and digoxin upon atrioventricular refractory period in the dog",
abstract = "The ability of digoxin and a 4-aminocardenolide, ASI-222, to alter atrioventricular nodal refractory period (AVRP) was determined as a function of the maximum subarrhythmic dose (MSAD) in the dog anesthetized with morphine-pentobarbital. ASI-222, a highly polar and potent inhibitor of Na+, K+-adenosine triphosphatase produces a cardiotoxicity in dogs prominently involving atrioventricular nodal blockade rather than ventricular premature ectopic beats and tachycardia seen with digoxin. AVRP was assessed with trains of electrically isolated stimuli of decreasing pulse interval delivered to the right atria. Digoxin and ASI-222 were infused i.v. at rates which produced cardiac arrhythmias in about 100 min in dogs either: with intact nerves, pretreated with atropine, without reflex receptors (without vagus and carotid sinus nerves, without cardiac sympathetic nerves and adrenals or pretreated with metoprolol. In dogs with intact nerves, ASI-222 produced greater increases in AVRP than digoxin at fractions of the MSAD; however, both glycoside produced a similar elevation at the MSAD (~30{\%} increase). Atropine did not alter the AVRP response to ASI-222 but prevented the lengthening due to digoxin except for that which occurred near the MSAD. Removal of reflex receptor afferents (and vagi) had an effect similar to atropine on the AVRP response to digoxin, but completely prevented any response to ASI-222. Prior sympathectomy or beta adrenergic blockade abolished the AVRP response to ASI-222 but did not alter the responses to digoxin. Our data indicate that ASI-222 increases AVRP by inhibiting cardiac sympathetic nervous influences in contrast to the effects of digoxin which are exerted mainly through vagal and direct means. Furthermore, they suggest the aminocardenolide increases AVRP more effectively at subarrhythmic doses than does digoxin.",
author = "Caldwell, {R. W.} and Nash, {C. B.}",
year = "1985",
month = "12",
day = "1",
language = "English (US)",
volume = "235",
pages = "583--588",
journal = "The Journal of pharmacology and experimental therapeutics",
issn = "0022-3565",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "3",

}

TY - JOUR

T1 - Effect of an aminocardenolide and digoxin upon atrioventricular refractory period in the dog

AU - Caldwell, R. W.

AU - Nash, C. B.

PY - 1985/12/1

Y1 - 1985/12/1

N2 - The ability of digoxin and a 4-aminocardenolide, ASI-222, to alter atrioventricular nodal refractory period (AVRP) was determined as a function of the maximum subarrhythmic dose (MSAD) in the dog anesthetized with morphine-pentobarbital. ASI-222, a highly polar and potent inhibitor of Na+, K+-adenosine triphosphatase produces a cardiotoxicity in dogs prominently involving atrioventricular nodal blockade rather than ventricular premature ectopic beats and tachycardia seen with digoxin. AVRP was assessed with trains of electrically isolated stimuli of decreasing pulse interval delivered to the right atria. Digoxin and ASI-222 were infused i.v. at rates which produced cardiac arrhythmias in about 100 min in dogs either: with intact nerves, pretreated with atropine, without reflex receptors (without vagus and carotid sinus nerves, without cardiac sympathetic nerves and adrenals or pretreated with metoprolol. In dogs with intact nerves, ASI-222 produced greater increases in AVRP than digoxin at fractions of the MSAD; however, both glycoside produced a similar elevation at the MSAD (~30% increase). Atropine did not alter the AVRP response to ASI-222 but prevented the lengthening due to digoxin except for that which occurred near the MSAD. Removal of reflex receptor afferents (and vagi) had an effect similar to atropine on the AVRP response to digoxin, but completely prevented any response to ASI-222. Prior sympathectomy or beta adrenergic blockade abolished the AVRP response to ASI-222 but did not alter the responses to digoxin. Our data indicate that ASI-222 increases AVRP by inhibiting cardiac sympathetic nervous influences in contrast to the effects of digoxin which are exerted mainly through vagal and direct means. Furthermore, they suggest the aminocardenolide increases AVRP more effectively at subarrhythmic doses than does digoxin.

AB - The ability of digoxin and a 4-aminocardenolide, ASI-222, to alter atrioventricular nodal refractory period (AVRP) was determined as a function of the maximum subarrhythmic dose (MSAD) in the dog anesthetized with morphine-pentobarbital. ASI-222, a highly polar and potent inhibitor of Na+, K+-adenosine triphosphatase produces a cardiotoxicity in dogs prominently involving atrioventricular nodal blockade rather than ventricular premature ectopic beats and tachycardia seen with digoxin. AVRP was assessed with trains of electrically isolated stimuli of decreasing pulse interval delivered to the right atria. Digoxin and ASI-222 were infused i.v. at rates which produced cardiac arrhythmias in about 100 min in dogs either: with intact nerves, pretreated with atropine, without reflex receptors (without vagus and carotid sinus nerves, without cardiac sympathetic nerves and adrenals or pretreated with metoprolol. In dogs with intact nerves, ASI-222 produced greater increases in AVRP than digoxin at fractions of the MSAD; however, both glycoside produced a similar elevation at the MSAD (~30% increase). Atropine did not alter the AVRP response to ASI-222 but prevented the lengthening due to digoxin except for that which occurred near the MSAD. Removal of reflex receptor afferents (and vagi) had an effect similar to atropine on the AVRP response to digoxin, but completely prevented any response to ASI-222. Prior sympathectomy or beta adrenergic blockade abolished the AVRP response to ASI-222 but did not alter the responses to digoxin. Our data indicate that ASI-222 increases AVRP by inhibiting cardiac sympathetic nervous influences in contrast to the effects of digoxin which are exerted mainly through vagal and direct means. Furthermore, they suggest the aminocardenolide increases AVRP more effectively at subarrhythmic doses than does digoxin.

UR - http://www.scopus.com/inward/record.url?scp=0022351677&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022351677&partnerID=8YFLogxK

M3 - Article

C2 - 4078725

AN - SCOPUS:0022351677

VL - 235

SP - 583

EP - 588

JO - The Journal of pharmacology and experimental therapeutics

JF - The Journal of pharmacology and experimental therapeutics

SN - 0022-3565

IS - 3

ER -